Trial ID or NCT#



not recruiting iconNOT RECRUITING


This phase I/II trial studies the best dose and timing of panitumumab-IRDye800 in detecting cancer in participants with lung cancer during the surgery. Panitumumab-IRDye800 is a combination of the antibody drug panitumumab and IRDye800CW, an investigational dye that can be seen using a special camera. Panitumumab-IRDye800 may attach to tumor cells and make them more visible during surgery in patients with lung cancer.

Official Title

A Phase I/II Study Evaluating the Safety and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Lung Cancer During Surgical Procedures

Eligibility Criteria

Ages Eligible for Study: Older than 19 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Natalie Shaubie Lui
Natalie Shaubie Lui
Thoracic surgeon
Assistant Professor of Cardiothoracic Surgery (Thoracic Surgery)
Eben Rosenthal
Eben Rosenthal
Otolaryngologist, Head and neck surgeon
Professor of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiology (Molecular Imaging Program at Stanford)

Contact us to find out if this trial is right for you.


Roan Courtney Raymundo
(650) 721-4071